Maravai Lifesciences Holdings (MRVI) Non-Current Debt (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly Non-Current Debt of $241.0 million for Q1 2026, down 16.75% year-over-year from $289.5 million in Q1 2025, and down 15.83% quarter-over-quarter from $286.3 million in Q4 2025.
Maravai Lifesciences Holdings (MRVI) Non-Current Debt (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Non-Current Debt history runs 7 years deep, the most recent figure standing at $241.0 million for Q1 2026.
- In Q1 2026, Non-Current Debt fell 16.75% year-over-year to $241.0 million; the TTM figure through Mar 2026 stood at $241.0 million (down 16.75% YoY), while the FY2025 annual figure was $286.3 million, down 3.24% from the prior year.
- Non-Current Debt for Q1 2026 stood at $241.0 million, down from $286.3 million in the prior quarter.
- The five-year high for Non-Current Debt was $711.2 million in Q2 2022, with the low at $241.0 million in Q1 2026.
- The 5-year median for Non-Current Debt is $517.9 million (2024), against an average of $468.0 million.
- The sharpest annual moves came in 2022 and 2025: Non-Current Debt jumped 35.32% in 2022, then slumped 44.34% in 2025.
- Maravai Lifesciences Holdings' Non-Current Debt stood at $522.0 million in 2022, then climbed by 0.41% to $524.1 million in 2023, then tumbled by 43.54% to $295.9 million in 2024, then retreated by 3.24% to $286.3 million in 2025, then declined by 15.83% to $241.0 million in 2026.
- Business Quant data shows MRVI's Non-Current Debt at $241.0 million in Q1 2026, $286.3 million in Q4 2025, and $287.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Maravai Lifesciences Holdings | 1.48 Bn | 1.56 Bn | 20.65 Mn | 147.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 147.11 Mn |
| Mar 31, 2026 | 241.01 Mn |
| Dec 31, 2025 | 286.33 Mn |
| Sep 30, 2025 | 287.38 Mn |
| Jun 30, 2025 | 288.44 Mn |
| Mar 31, 2025 | 289.50 Mn |
| Dec 31, 2024 | 295.93 Mn |
| Sep 30, 2024 | 516.28 Mn |
| Jun 30, 2024 | 517.08 Mn |
| Mar 31, 2024 | 517.89 Mn |
| Dec 31, 2023 | 524.15 Mn |
| Sep 30, 2023 | 519.52 Mn |
| Jun 30, 2023 | 520.34 Mn |
| Mar 31, 2023 | 677.39 Mn |
| Dec 31, 2022 | 522.00 Mn |
| Sep 30, 2022 | 711.23 Mn |
| Jun 30, 2022 | 711.23 Mn |
| Mar 31, 2022 | 529.94 Mn |
| Dec 31, 2021 | 530.59 Mn |
| Sep 30, 2021 | 525.58 Mn |